% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Jul 24, 2013 11:37 AM Flag

    INSM reality check

    IBD ratings are only valid with revenue producing companies. Insmed hopes to be delivering revenues in 2 years........Insmed currently carries a Zacks Rank #4 (Sell)...... All 5 brokerages who follow Insmed were paid from offerings by Insmed, inc. in the past 2 years..... The current valuation is not a paid analyst, a chart or a stupid posters's $9.77. .... with the not so compelling Phase3 results and the dilution done, news of a different kind awaits. ....As far as a chart read, its very clear Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So in your estimation\\\if another trial for Cystic Fibrosis is asked of Insmed\\they will do the trial? Is $9.77 where we are headed?

    • Gosh! how did the banks decide? ...and what the short interest report this eve WONT tell you.... July 1- Phase3 data of inferiority is released the stock closes @ $9.72 Hello!.
      If the company plans a Phase3 in the US , the banks paid too much. If the company is allowed to file they probably paid about the right price, if the FDA finds problems in the data, the banks paid too much.
      If NTM fails the banks paid WAAAAAY too much.The banks valued Insmed around 400 Million. There is risk going forward. YTD 117% in the bank , and my short blindsided by the dilution will be flat soon. Good Luck

    • "All 5 brokerages who follow Insmed were paid from offerings by Insmed, inc. in the past 2 years"

      As every regular user of this forum knows you're the resident Star Clown, and that you post whatever lies you think might make you look important, I guess I'll ask the question for everybody -

      Where is your proof that UBS has been paid by Insmed?

14.57-0.19(-1.29%)Sep 26 4:00 PMEDT